Coronavirus disease, transmission of COVID 19, signs and symptoms of COVID 19, how it affects respiratory system, pathogenesis of COVID 19, prevention from COVID, vaccine development. COVID 19 pandemic
2. Coronavirus
• Coronaviruses are a family of viruses that can cause
illnesses such as the common cold, severe acute
respiratory syndrome (SARS) and Middle East
respiratory syndrome (MERS). In 2019, a new
coronavirus was identified as the cause of a disease
outbreak that originated in China.
• The disease it causes is called coronavirus disease 2019
(COVID-19).
• In March 2020, the World Health Organization (WHO)
declared the COVID-19 outbreak a pandemic.
14 July 2020Shalu Thariwal
3. Transmission and risk factors
• The virus spreads by respiratory droplets released when
someone with the virus coughs, sneezes or talks. These
droplets can be inhaled or land in the mouth or nose of a
person nearby.
• It can also spread if a person touches a surface with the
virus on it and then touches his or her mouth, nose or
eyes.
Risk factors
• Recent travel from or residence in an area with ongoing
community spread of COVID-19
• Close contact with someone who has COVID-19
14 July 2020Shalu Thariwal
4. Signs and symptoms
• Fever
• Cough
• Tiredness
• Early symptoms of COVID-19 - loss of taste or smell.
Other symptoms
• Shortness of breath or difficulty breathing
• Muscle aches
• Chills
• Sore throat
• Runny nose
• Headache
• Chest pain
14 July 2020Shalu Thariwal
7. Respiratory system
• The new coronavirus can infect the upper or lower a part
of the breathing tract. It travels down in airways. The
lining can become irritated and inflamed. In some cases,
the contamination can reach the entire manner down into
alveoli. COVID-19 is a brand new condition, and
scientists are learning greater each day about what it can
do on lungs.
• Cell invasion and viral replication in the nose
• Replication in the lung and immune system alerted
• Pneumonia
• Acute respiratory distress syndrome, the cytokine storm,
and multiple organ failure
14 July 2020Shalu Thariwal
8. Cont…
• Diffuse alveolar damage with varying degrees of
acute exudative features including edema and hyaline
membranes, organization, and fibrosis. Macrophagic
or mixed cellular infiltration, multinuclear giant cells,
atypical reactive pneumocytes, and vascular injury.
• 1) extensive edema,
• 2) hyaline membrane formation,
• 3) collapse of alveoli,
• 4) desquamation of alveolar epithelial cells, and
• 5) fibrous tissue in alveolar spaces.
14 July 2020Shalu Thariwal
10. Prevention
• Avoid large events and mass gatherings.
• Avoid close contact (within about 6 feet, or 2 meters)
• Stay home as much as possible and keep distance between
yourself and others.
• Wash your hands often with soap and water for at least 20
seconds, or use an alcohol-based hand sanitizer that contains at
least 60% alcohol.
• Cover your face with a cloth face mask in public spaces.
• Avoid touching your eyes, nose and mouth.
• Avoid sharing dishes, glasses, towels, bedding and other
household items if you're sick.
• Clean and disinfect high-touch surfaces, such as doorknobs,
light switches, electronics and counters, daily.
14 July 2020Shalu Thariwal
12. Pathways to develop and produce a
COVID-19 vaccine
Global health authorities and vaccine developers are
currently partnering to support the technology needed to
produce vaccines.
• Live vaccines use a weakened (attenuated) form of the
germ that causes a disease. This kind of vaccine prompts
an immune response without causing disease.
• Inactivated vaccines use a killed (inactive) version of the
germ that causes a disease. This kind of vaccine causes an
immune response but not infection.
• Genetically engineered RNA or DNA vaccines
14 July 2020Shalu Thariwal
14. References
• Cheung OY, Chan JW, Ng CK, Koo CK. The spectrum of pathological changes in severe acute respiratory
syndrome (SARS). Histopathology. 2004;45:119–124. [PMC free article] [PubMed] [Google Scholar]
• Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe
acute respiratory syndrome in Toronto. Mod Pathol. 2005;18:1–10. [PMC free article] [PubMed] [Google
Scholar]
• Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, Selbs E, McEvoy CPL, Hayden CDL,
Fukuoka J, Taubenberger JK, Travis WD. Lung pathology of severe acute respiratory syndrome (SARS): a
study of 8 autopsy cases from Singapore. Hum Pathol. 2003;34:743–748. [PMC free article] [PubMed]
[Google Scholar]
• Hsiao CH, Wu MZ, Chen CL, Hsueh PR, Hsieh SW, Yang PC, Su IJ. Evolution of pulmonary pathology in
severe acute respiratory syndrome. J Formos Med Assoc. 2005;104:75–81. [PubMed] [Google Scholar]
• Nakajima N, Asahi-Ozaki Y, Nagata N, Yko S, Dizon F, Paladin FJ, Olveda RM, Odagiri T, Masato T, Sata
T. SARS coronavirus-infected cells in lung detected by new in situ hybridization technique. Jpn J Infect
Dis. 2003;56:139–141. [PubMed] [Google Scholar]
• He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Li Z, Zhao L, Geng J, Deng Y, Yang L, Li J, Cai J,
Qiu L, Wen K, Xu X, Jiang S. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-
infected ACE2(+) cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J
Pathol. 2006;210:288–297. [PMC free article] [PubMed] [Google Scholar]
• Gu.J and Kortewerg. Pathology and Pathogenesis of Severe Acute Respiratory Syndrome. Am J Pathol.
2007 Apr; 170(4): 1136–1147. doi: 10.2353/ajpath.2007.061088
14 July 2020Shalu Thariwal